BRAF V600E-mutated BTC has been more recently associated with higher tumor-node-metastasis (TNM) stage, resistance to systemic chemotherapy, aggressive clinical course and worse survival [76, 77], although early studies suggested no correlation between survival and BRAF mutations. The gene discussed is BRAF; the disease is neoplasm.